Michael Wyzga - Mereo Biopharma Non-Executive Director

MREO
 Stock
  

USD 1.15  0.02  1.71%   

  Director
Mr. Michael S. Wyzga is NonExecutive Director of the Company. Michael Wyzga served as a director of OncoMed from October 2013 until the closing of the Merger today. Mr. Wyzga is currently the President of MSW Consulting Inc., a strategic consulting group focused in the life sciences area. From December 2011 until November 2013, Mr. Wyzga served as President and Chief Executive Officer and a member of the board of directors of Radius Health, Inc. Prior to that, Mr. Wyzga served in various senior management positions at Genzyme Corporationrationration, including as Chief Financial Officer from July 1999 until November 2011. Mr. Wyzga is a member of the boards of directors of Exact Sciences Corporationrationration and LogicBio and is Chairman of the board of directors of GenSight Biologics S.A. and of X4 Biologics
Age: 63  Director Since 2019  MBA    
44 33 3023 7300  https://www.mereobiopharma.com
Wyzga previously served as a member of the boards of directors of Idenix Pharmaceuticals, Inc. and Altus Pharmaceuticals, Inc., and as a member of the supervisory board of Prosensa Holding B.V. He received an M.B.A. from Providence College and a B.S. from Suffolk University.

Mereo Biopharma Management Efficiency

Mereo Biopharma Group has return on total asset (ROA) of (13.82) % which means that it has lost $13.82 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 34.85 %, meaning that it created $34.85 on every $100 dollars invested by stockholders. Mereo Biopharma management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Return on Average Assets is expected to rise to 0.14 this year. Return on Average Equity is expected to rise to 0.38 this year. Mereo Biopharma Assets Non Current are quite stable at the moment as compared to the past year. The company's current value of Assets Non Current is estimated at 34.35 Million. Goodwill and Intangible Assets is expected to rise to about 31.5 M this year, although the value of Total Assets will most likely fall to about 117.3 M.
The company currently holds 16.76 M in liabilities with Debt to Equity (D/E) ratio of 0.19, which may suggest the company is not taking enough advantage from borrowing. Mereo Biopharma Group has a current ratio of 7.76, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Mereo Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Mereo Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mereo Biopharma Group sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mereo to invest in growth at high rates of return. When we think about Mereo Biopharma's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

DIRECTOR Since

John DonahoeIntel Corp
2009
Reed HundtIntel Corp
2001
Susan DeckerIntel Corp
2012
Charlene BarshefskyIntel Corp
2004
David YoffieIntel Corp
1989
Gregory SmithIntel Corp
2017
Risa LavizzoMoureyIntel Corp
2018
Robert SteinIntel Corp
2016
Stacy SmithIntel Corp
2016
Frank YearyIntel Corp
2009
Andrew WilsonIntel Corp
2017
Omar IshrakIntel Corp
2017
David PottruckIntel Corp
1998
TsuJae LiuIntel Corp
2016
Aneel BhusriIntel Corp
2017
James PlummerIntel Corp
2005
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom. Mereo Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 49 people. Mereo Biopharma Group (MREO) is traded on NASDAQ Exchange in USA. It is located in One Cavendish Place and employs 49 people. Mereo Biopharma is listed under Pharmaceutical Products category by Fama And French industry classification.

Mereo Biopharma Group Leadership Team

Elected by the shareholders, the Mereo Biopharma's board of directors comprises two types of representatives: Mereo Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mereo. The board's role is to monitor Mereo Biopharma's management team and ensure that shareholders' interests are well served. Mereo Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mereo Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Peter Bains, Non-Executive Independent Director
Kunal Kashyap, Non-Executive Director
Deepa Pakianathan, Non-Executive Director
Paul Blackburn, Non-Executive Independent Director
Alastair MacKinnon, Chief Medical Officer and Co-Founder
Michael Wyzga, Non-Executive Director
Richard Jones, CFO, Executive Director
Richard Francis, Head of Pharmaceutical Development
John Richard, Head of Corporate Development and Co-Founder
Charles Sermon, Co-Founder, General Counsel, Secretary
Denise ScotsKnight, CEO, Co-Founder, Executive Director
Peter Fellner, Independent Non-Executive Chairman of the Board
Anders Ekblom, Non-Executive Independent Director

Mereo Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mereo Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Mereo Biopharma Investors Sentiment

The influence of Mereo Biopharma's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Mereo. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Mereo Biopharma's public news can be used to forecast risks associated with investment in Mereo. The trend in average sentiment can be used to explain how an investor holding Mereo can time the market purely based on public headlines and social activities around Mereo Biopharma Group. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Mereo Biopharma's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Mereo Biopharma's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Mereo Biopharma's news discussions. The higher the estimate score, the more favorable is the investor's outlook on Mereo Biopharma.

Mereo Biopharma Implied Volatility

    
  199.01  
Mereo Biopharma's implied volatility exposes the market's sentiment of Mereo Biopharma Group stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Mereo Biopharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Mereo Biopharma stock will not fluctuate a lot when Mereo Biopharma's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Mereo Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Mereo Biopharma's short interest history, or implied volatility extrapolated from Mereo Biopharma options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Mereo Biopharma Group using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Note that the Mereo Biopharma Group information on this page should be used as a complementary analysis to other Mereo Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Watchlist Optimization module to optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm.

Complementary Tools for Mereo Stock analysis

When running Mereo Biopharma Group price analysis, check to measure Mereo Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mereo Biopharma is operating at the current time. Most of Mereo Biopharma's value examination focuses on studying past and present price action to predict the probability of Mereo Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Mereo Biopharma's price. Additionally, you may evaluate how the addition of Mereo Biopharma to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Is Mereo Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo Biopharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
138 M
Return On Assets
-0.14
Return On Equity
0.35
The market value of Mereo Biopharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo Biopharma's market value can be influenced by many factors that don't directly affect Mereo Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Mereo Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.